Drug Use May Shift Under US Medicare Oncology Care Model; Here’s How
‘Episode of care’ payment model could reduce off-label cancer drug prescribing but also offers an opportunity for increased use of high-value drugs, including those that can reduce costs by decreasing hospitalizations, University of Chicago’s Rena Conti suggests.
You may also be interested in...
The 800-Lb. Gorilla: Drug Costs Loom Large In Medicare Oncology Care Model
Drug costs make up 60% of the total cost of cancer care, participants in the Medicare Oncology Care Model have found. But efforts to manage spending under the demonstration have so far focused instead on areas that represent a smaller portion of overall costs, such as hospitalizations.
US Medicare Oncology Demo Should Test Value-Based Drug Pricing – Providers
Community Oncology Alliance proposes updates to the Oncology Care Model demonstration project, including a sharper focus on lowering prescription drug costs.
Value-Based Payment Experiments For Drugs To Be Key Focus For CMMI, Director Says
Recently-installed Center for Medicare and Medicaid Innovation Chief Adam Boehler says payment lab will play a role in the Administration’s overall approach to lowering prescription drug costs.